Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. two-birds

TWO-BIRDS SIGNED

A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TWO-BIRDS project word cloud

Explore the words cloud of the TWO-BIRDS project. It provides you a very rough idea of what is the project "TWO-BIRDS" about.

risk    population    ineffective    psychological    pharmaceutical    provoke    demonstrated    pharma    unfortunately    disorder    master    investor    deals    70    feasibility    paradigm    nightmares    treatment    patient    balance    establishing    clinical    compound    experiences    termed    patients    regulatory    companies    molecule    stage    never    million    flashbacks    first    trauma    stress    modulate    unforgiving    regulate    15    safe    severe    drug    commercialize    neuroregulator    510    restore    disorders    traumatic    mechanism    chemistry    neural    circuit    relive    anxiety    combined    sustainable    anti    inhibitors    ptsd    preclinical    thereby    co    market    restoring    birds    small    seris    intrusive    eventual    business    profile    sales    post    action    family    brain    attractive    pharmacokinetic    triggers    synendos    final    downstream    clinician    endocannabinoid    understand    manner    function    hold    dependency    consolidate    drugs    symptoms    self    reuptake    plan    circuits    cognitive    start    disrepair    syt    relief    people    endocx    ready    limiting    selective    partnering    victims    chemistries    coerced    dysregulated    thoughts    safety   

Project "TWO-BIRDS" data sheet

The following table provides information about the project.

Coordinator		 SYNENDOS THERAPEUTICS AG 

Organization address
address: SWISS INNOVATION PARK, GEWERBESTRASSE 24
city: ALLSCHWIL
postcode: 4123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNENDOS THERAPEUTICS AG CH (ALLSCHWIL) coordinator 50˙000.00

Map

 Project objective

PTSD affects over 15 million people in Europe. So far, 70% never find relief. New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.

Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders. As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, nightmares and severe anxiety. Unfortunately, current drugs address only specific downstream neural circuits and are highly ineffective. The endoCx is highly dysregulated in PTSD, and as a 'master neuroregulator', drugs that restore its function in a safe and sustainable manner have strong potential to be the first effective treatment for PTSD.

Synendos is a pharmaceutical start-up who have identified a new family of drugs that modulate the endoCx via a new mechanism-of-action. Termed SERIs, or, ‘selective endocannabinoid reuptake inhibitors’, these small molecule drugs regulate the endoCx system in a self-limiting manner, thereby restoring balance to brain chemistry without risk of drug dependency or cognitive disrepair. Our lead compound SYT-510 is at the stage of preclinical development, where it has demonstrated effective anti-anxiety activity, favourable pharmacokinetic characteristics and a strong safety profile.

We aim to commercialize SYT-510 through establishing partnering deals with pharma companies for its co-development and eventual sales. With a patient population of over 30 million (in EU/US combined), PTSD is an attractive market for drug development.

TWO-BIRDS project: The main aims of this feasibility study are to 1) work to further understand clinician and patient needs, 2) define a detailed plan for final preclinical, clinical and regulatory activities and 3) consolidate new information into an investor-ready business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TWO-BIRDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TWO-BIRDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More